Antibody responses to acute COVID-19 infection; assessment via multiplex LABScreen COVID Plus Assay | ||||
| Microbes and Infectious Diseases | ||||
| Article 6, Volume 3, Issue 3, August 2022, Page 544-553 PDF (318.38 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mid.2022.138557.1315 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nora M. Said1; Mohammad Walaa2; Dina Gamal1; Rania Amer   3; Alshymaa A. Ahmed 1
| ||||
| 1Clinical Pathology Department, Faculty of Medicine, Zagazig University | ||||
| 2Chest Department, Faculty of Medicine, Zagazig University | ||||
| 3Medical Microbiology and Immunology department, Faculty of Medicine and Scientific and Medical Research Center, Zagazig University | ||||
| Abstract | ||||
| Background: Understanding the profile of antibody responses following acute COVID-19 infection is required. Aim: to describe the pattern of IgG anti-COVID-19 antibody production in patients with acute infection using the LABScreen COVID Plus assay. Results: The overall seropositivity was 69/73(94.5%). Anti-Spike, Spike 1 and spike S2 subunits were positive in 78.1%, while anti spike receptor binding domain (RBD) was detected in 68.4% and anti nucleocapsid protein in 61.6%. The overall positivity of the assay reached 100.0% during the second week post symptoms. The mean fluorescent intensities (MFI) of anti-Spike S1 was higher in the second week than the first week, p < /em>=0.03. MFI of anti-Spike S2 was significantly higher in PCR positive patients in comparison with the negative ones, p < /em>=0.006. When compared to the RT-PCR results; the overall antibodies positivity, anti-Spike, and anti-Spike2 antibodies had sensitivities (100% and 84.7%) and specificities (28.6% and 50.0%) and accuracies (86.3% and 78.1%). Patients' outcome correlated significantly with the time of hospital admission, p < /em>=0.001. Conclusion: COVID-19 IgG antibodies are detectable with considerable frequencies during the first two weeks post infection. Anti S2 antibodies correlates well with the RT-PCR results. The LABScreen COVID Plus is a sensitive assay for the detection of post-acute COVID-19 infection antibody responses. Background: Understanding the profile of antibody responses following acute COVID-19 infection is required. Aim: to describe the pattern of IgG anti-COVID-19 antibody production in patients with acute infection using the LABScreen COVID Plus assay. Results: The overall seropositivity was 69/73(94.5%). Anti-Spike, Spike 1 and spike S2 subunits were positive in 78.1%, while anti spike receptor binding domain (RBD) was detected in 68.4% and anti nucleocapsid protein in 61.6%. The overall positivity of the assay reached 100.0% during the second week post symptoms. The mean fluorescent intensities (MFI) of anti-Spike S1 was higher in the second week than the first week, p < /em>=0.03. MFI of anti-Spike S2 was significantly higher in PCR positive patients in comparison with the negative ones, p < /em>=0.006. When compared to the RT-PCR results; the overall antibodies positivity, anti-Spike, and anti-Spike2 antibodies had sensitivities (100% and 84.7%) and specificities (28.6% and 50.0%) and accuracies (86.3% and 78.1%). Patients' outcome correlated significantly with the time of hospital admission, p < /em>=0.001. Conclusion: COVID-19 IgG antibodies are detectable with considerable frequencies during the first two weeks post infection. Anti S2 antibodies correlates well with the RT-PCR results. The LABScreen COVID Plus is a sensitive assay for the detection of post-acute COVID-19 infection antibody responses. | ||||
| Keywords | ||||
| Antibodies; COVID-19; performance; real-time PCR; sensitivities | ||||
|
Statistics Article View: 270 PDF Download: 211 |
||||
